Osivax Announces Promising Phase 2a Results with Universal Influenza Vaccine Candidate, OVX836, and Initiation of Additional Phase 2a Dose Optimization Study Phase 2a results demonstrate excellent safety profile alongside strong, dose-dependent immune response First patient enrolled in complementary Phase 2a dose optimization study Lyon, France – December 21st, 2021 – Osivax, a biopharmaceutical company focused …
Archives de l’auteur : Marianne Duparc
Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases
Osivax Announces Publication of Phase 1 Data on its Broad-Spectrum Influenza Vaccine Candidate OVX836 in the Journal of Infectious Diseases Encouraging safety and cellular immune response data as well as a promising reactogenicity profile warrant further evaluation of OVX836 in Phase 2a study Lyon, France – December 2nd, 2021 – Osivax, a biopharmaceutical company focused …
ISIRV-WHO
Virtual – PosterAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to present the last clinical results of OVX836 as part of a poster entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
A Day @Bioaster
Lyon – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide a general update on OVX836 as part of a presentation entitled « the development of a universal influenza vaccine: a precision approach to control diversity – NP as an attractive target for T cell based universal flu vaccine. »
Vaccine Summit 2021
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
Global Conference on Vaccines Research and Development
Virtual – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide the last clinical results of OVX836 as part of a presentation entitled « OVX836, NP-based universal influenza vaccine candidate: results of phase 2a clinical trial ».
2020 Vaccinology Club of French Society for Immunology
Lille – Oral PresentationFlorence Nicolas, Director of R&D and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza vaccine candidate: Short-term results of the Phase 1 clinical trial ».
5th international Conference on Vaccines R&D
Boston – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».
World Vaccine Congress Europe
Barcelona – Oral PresentationAlexandre Le Vert, Chief Executive Officer and Co-founder of Osivax, to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ».
OPTIONS X
Singapore – Oral Presentations and PostersAlexandre Le Vert to provide clinical results of OVX836 as part of a presentation entitled « A novel universal influenza A vaccine candidate: a Phase 1 clinical trial in humans ». Delphine Guyon-Gellin and Nicolas Noulin (hVIVO) to present « Pre-existing NP specific T-cell response correlates with reduction of symptoms in a human …